RxDoctor Payments Data

Cheryl Waters, MD

Neurology · New York, NYNPI 1356395446

Payments from drug & device makers

$762,601in general payments, 2019–2025

Across 260 payments — averaging $2933.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$355K
  • Biogen$109K
  • Acorda Therapeutics, Inc$57K
  • UCB SA$50K
  • Sunovion Pharmaceuticals Inc.$43K
  • Acadia Pharmaceuticals Inc$41K
  • plus $108K from 11 others
$3,498in research payments, 2019–2025

Across 8 payments — averaging $437.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Kyowa Kirin Pharmaceutical Development, Inc$2K
  • Sanofi$1K

What the payments were for

  • Consulting fees$49,66326%
  • Speaking & faculty fees$126,13667%
  • Travel & lodging$10,2245%
  • Food & beverage$3,3412%
  • Education$10%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$762,601 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$155,202
Medicare patients
466
Services billed
1,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate79$556,586
GocovriAmantadine Hcl74$226,345
RytaryCarbidopa/Levodopa54$59,922
InbrijaLevodopa12$51,071
Carbidopa-LevodopaCarbidopa/Levodopa902$41,143
Droxidopa25$37,824
NeuproRotigotine24$29,571
XadagoSafinamide Mesylate11$17,836
Carbidopa-Levodopa ErCarbidopa/Levodopa323$14,150
MyrbetriqMirabegron15$8,293
Rivastigmine25$6,903
AmantadineAmantadine Hcl89$4,132
Rasagiline Mesylate31$3,261
Orphenadrine Citrate ErOrphenadrine Citrate23$1,815
Ropinirole ErRopinirole Hcl21$1,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$40,687$556,58679 claims
MDD US Operations, LLCGocovri$26,986$226,34574 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$21,782$61,00074 claims
Acorda Therapeutics, IncInbrija$56,739$51,07112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →